Is Fadogia agrestis worth it?
Fadogia agrestis is testosterone hype built mostly on rat data and podcast-driven demand, not human clinical evidence. The category asks buyers to accept hormone claims and reproductive-safety uncertainty at the same time, which is the wrong trade.
The call
The testosterone claim rests on preclinical Fadogia agrestis studies in male rats, not randomized human trials showing meaningful changes in testosterone, symptoms, fertility, strength, or health outcomes. Rodent libido or hormone findings are not enough to sell a human endocrine supplement, especially when the human dose, extract standardization, active compounds, and long-term safety are undefined. Medical testosterone guidelines start with symptoms plus confirmed lab testing because hormones are not a casual optimization target. Fadogia therefore lands as unsubstantiated and skip: the retail claim is ahead of the evidence and the safety margin is not reassuring.
Safety
Avoid during pregnancy, breastfeeding, adolescence, fertility attempts, known infertility, prostate disease, testicular disease, hormone-sensitive cancers, mood instability, liver disease, kidney disease, or unexplained sexual, fertility, breast, testicular, or prostate symptoms. Do not combine with testosterone, anabolic steroids, SERMs, aromatase inhibitors, fertility drugs, or other hormone-modifying supplements without medical supervision. Product identity and extract strength are not standardized, and preclinical reproductive-organ findings raise enough concern to avoid chronic use. Stop use and seek care for testicular pain, breast tenderness, severe acne, mood changes, palpitations, abdominal pain, dark urine, jaundice, or allergic symptoms.
Dose that matters: -; no validated human testosterone, libido, fertility, or performance dose exists. Do not translate rodent extract dosing into a human hormone protocol, and do not treat retail capsule serving sizes as evidence-based dosing.
Sources
Tier 2 · evidence synthesis · Reviewed by the Stack-kit desk